▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Jim Crumly

TMFSpeyside

Jim bought his first stocks in 1967 with paper route money and has been invested in equities ever since. He's still learning, though, and enjoys studying and investing in a wide variety of businesses. He has a BS and MS in electrical engineering from Stanford University, and retired after 34 years with a large technology company.

Recent Articles by Jim Crumly

GettyImages-1179385252

Feb 28, 2021 by Jim Crumly

3 Great Stocks for Low-Risk Investors

These companies with low-risk businesses will hold up over the long run.

GettyImages-1194077256

Feb 15, 2021 by Jim Crumly

3 Healthcare Stocks I'd Buy Right Now

Two innovative small companies with scorching growth and one bargain biotech.

GettyImages-1227074505

Feb 11, 2021 by Jim Crumly

3 Absurdly Cheap Coronavirus Stocks to Buy Now

These stocks would be buys even without the pandemic.

GettyImages-1213468623

Mar 10, 2021 by Jim Crumly

What the COVID-19 Variants Mean for Vaccine Makers

This risk to public health is causing a strategic shift by the various developers.

GettyImages-1194521388

Feb 3, 2021 by Jim Crumly

Jazz Pharmaceuticals to Acquire Cannabis Drug Company

The deal to buy GW Pharmaceuticals creates a leader in neuroscience.

GettyImages-849081626

Jan 29, 2021 by Jim Crumly

Johnson & Johnson Says Its One-Dose Coronavirus Vaccine Was 66% Effective in Clinical Trial

The vaccine was 100% effective in preventing hospitalization and death from COVID-19.

GettyImages-1213545891

Jan 28, 2021 by Jim Crumly

Could This Drug Be 100% Effective in Preventing Symptomatic COVID-19 Infections?

Strong interim trial data boosts the prospects for a treatment already worth billions.

GettyImages-1212321498

Jan 27, 2021 by Jim Crumly

Merck Gives Up on Coronavirus Vaccines

The company will focus on antiviral and anti-inflammatory treatments for patients infected with COVID-19.

GettyImages-1219398943

Jan 25, 2021 by Jim Crumly

Moderna Says Vaccine Protects Against All Known Variants

A weaker response to the South African variant prompts studies of a strain-specific booster.

GettyImages-1267929704

Jan 20, 2021 by Jim Crumly

Pfizer and BioNTech Report Evidence That Their Vaccine Is Effective Against COVID-19 Variant

A new study bolsters confidence in the mRNA vaccine.

GettyImages-1250573460

Jan 5, 2021 by Jim Crumly

Where Will Innovative Industrial Properties Be in 5 Years?

Can this profitable marijuana company keep up its winning streak?

GettyImages-1212440479

Dec 21, 2020 by Jim Crumly

Quidel Rapid Antigen Test for COVID-19 Wins Authorization

A new point-of-care test is both fast and accurate.

GettyImages-1023086612

Dec 19, 2020 by Jim Crumly

3 Top Mid-Cap Stocks to Buy Now

These companies are succeeding during the pandemic and will perform even better during a recovery.

GettyImages-812969616

Dec 16, 2020 by Jim Crumly

Forget the Vaccine. Here Are the Real Reasons AstraZeneca Stock Is a Buy

The market isn't focused on the real story with this stock. That will change.

GettyImages-944545988

Dec 13, 2020 by Jim Crumly

3 Top Pharma Stocks to Buy Now

Investors are shunning these stocks now, but that will change.

G6+family_flat_110+copy

Dec 9, 2020 by Jim Crumly

DexCom Has a Lot to Prove in 2021

Investors have a few questions as the company faces increasing competition.

Teladoc_Member_and_Child_on_Video_Visit

Nov 30, 2020 by Jim Crumly

Should You Sell Teladoc Health Stock As Coronavirus Vaccines Succeed?

Investors are worried that Teledoc Health stock will fade along with the pandemic.

Pills

Nov 28, 2020 by Jim Crumly

Is AbbVie a Great Dividend Stock?

The stock has a high yield -- and it also has something even more important.

GettyImages-1164584480

Nov 27, 2020 by Jim Crumly

3 Bargain Stocks You Can Buy Today

Investors have been selling these stocks, but patient investors should take advantage of the opportunity.

GettyImages-663613046

Nov 26, 2020 by Jim Crumly

This Small-Cap Stock Will Be a Long-Term Winner From the Pandemic

Wall Street seems worried that the arrival of coronavirus vaccines will take the wind out of the sails of this genetic and medical testing company. That view misses the big picture.

HOW THE MOTLEY FOOL CAN HELP YOU

Motley Fool Returns

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns

803%

S&P 500 Returns

172%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/15/2024.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

Chart Showing the Cumulative Growth of a $10,000 Investment in Stock Advisor

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services